› Lobbying pays off for drugmaker in budget bill,
WASHINGTON — Tucked in the massive congressional budget bill is a provision that props up the price Medicare pays for a handful of medications, costing taxpayers millions at a time when the Trump administration is vowing to reduce the cost of prescription drugs.
Lawmakers acted after a lobbying campaign by a small Washington state pharmaceutical company called Omeros. Its main product is a drug called Omidria, used by hospitals in cataract surgery, which recently had lost a coveted Medicare reimbursement status. Individuals associated with the company also stepped up their political contributions.
Rep. Cathy McMorris Rodgers of Washington, the fourth-ranking House Republican, took the issue to Speaker Paul Ryan, R-Wis., securing a place for the drug provision in the 2,232-page spending bill signed Friday by President Donald Trump, aides said. The provision restores the drug’s expired reimbursement status for two years, making it more lucrative for hospitals to continue using it.
The targeted provision succeeded even as broader health care measures failed to make the cut in the budget bill, from legislation to stabilize insurance premiums under the Affordable Care Act for millions of consumers, to a drug-industry backed effort to roll back recent changes that shift some Medicare costs to pharmaceutical companies.